Akari Therapeutics Plc Net Income Loss

• Akari Therapeutics Plc showed an increase of +12.6% in Net Income Loss from 2024 to 2025.
• This data is from Akari Therapeutics Plc's annual report (Form 10-K), filed with the SEC on March 30, 2026.
• XBRL data for this metric is available from 2006 to 2025 (20 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2014: -$1.74 million | Q2 2014: -$2.23 million | Q3 2014: -$223.1 thousand | Q1 2015: -$1.70 million | Q2 2015: -$1.67 million | Q3 2015: -$48.74 million | Q1 2016: -$2.99 million | Q1 2019: -$186.5 thousand | Q2 2019: -$5.95 million | Q3 2019: -$2.88 million | Q1 2020: -$3.75 million | Q2 2020: -$7.44 million | Q3 2020: $913.5 thousand | Q1 2023: $1.00 million | Q2 2023: -$4.00 million | Q3 2023: -$2.87 million | Q1 2024: -$5.57 million | Q2 2024: -$7.56 million | Q3 2024: -$2.90 million | Q1 2025: -$3.71 million | Q2 2025: -$1.90 million | Q3 2025: -$6.40 million.
• Over the full 20 years of available data (2006 to 2025), Akari Therapeutics Plc's Net Income Loss has declined by 877.8%.
• Historical annual values: Fiscal year 2025: -$17.30 million | Fiscal year 2024: -$19.79 million | Fiscal year 2023: -$10.01 million | Fiscal year 2022: -$17.75 million | Fiscal year 2021: -$17.42 million | Fiscal year 2020: -$17.08 million | Fiscal year 2019: -$16.85 million | Fiscal year 2018: -$20.50 million | Fiscal year 2017: -$35.40 million | Fiscal year 2016: -$18.14 million | Fiscal year 2015: -$45.32 million | Fiscal year 2014: -$1.95 million | Fiscal year 2013: -$3.62 million | Fiscal year 2012: -$4.27 million | Fiscal year 2011: -$2.12 million | Fiscal year 2010: -$675.0 thousand | Fiscal year 2009: -$1.01 million | Fiscal year 2008: -$1.44 million | Fiscal year 2007: -$3.13 million | Fiscal year 2006: -$1.77 million.
• Data sourced from SEC EDGAR public filings as of August 5, 2026.

Last verified: August 5, 2026